Results 111 to 120 of about 20,079 (290)

Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review

BMC Public Health
Background Adhering to varenicline has been shown to significantly improve the chances of successfully quitting smoking, with studies indicating a twofold increase in 6-month quit rates.
Nadia Minian, Melissa Wong, Sowsan Hafuth, Terri Rodak, Alma Rahimi, Dea Gjomema, Jonathan Rose, Laurie Zawertailo, Matt Ratto, Peter Selby   +9 more
doaj   +1 more source

Varenicline Targets the Reinforcing-Enhancing Effect of Nicotine on Its Associated Salient Cue During Nicotine Self-administration in the Rat

Frontiers in Behavioral Neuroscience, 2019
Nicotine is acknowledged as the key addictive compound of tobacco. Varenicline (Champix® or Chantix®), mainly acting as a partial agonist at the α4β2 nicotinic receptor, is an approved smoking cessation pharmacotherapy, although with efficacy limited to ...
Vernon Garcia-Rivas, Vernon Garcia-Rivas, Jean-François Fiancette, Jean-François Fiancette, Nazzareno Cannella, Nazzareno Cannella, Maria Carbo-Gas, Maria Carbo-Gas, Prisca Renault, Prisca Renault, Jessica Tostain, Jessica Tostain, Véronique Deroche-Gamonet, Véronique Deroche-Gamonet   +13 more
doaj   +1 more source

Changes in body weight and food choice in those attempting smoking cessation: a cluster randomised controlled trial [PDF]

, 2012
<p><b>Background:</b> Fear of weight gain is a barrier to smoking cessation and significant cause of relapse for many people. The provision of nutritional advice as part of a smoking cessation programme may assist some in smoking ...
AAWA van der Heijen, AC Parsons, Andrew Walker, AR Dyer, C Filozoff, Catherine R Hankey, F Pistelli, G Colletti, Heather M Murray, J Armstrong, J Stevens, JE Audrain, JE Cade, L Bauld, LR Purslow, MD Levine, MEJ Lean, MG Perri, Mhairi Mackenzie, Michael EJ Lean, P Hajek, Preethi R Koshy, R Ara, RC Klesges, S Chinn, S Rossner, St Stewart, Susan Boyle, Wilma S Leslie   +28 more
core   +3 more sources

Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial

Journal of Clinical Psychopharmacology, 2019
Background Neuropsychiatric safety and relative efficacy of varenicline, bupropion, and transdermal nicotine patch (NRT) in those with psychiatric disorders are of interest.
A. E. Evins, N. Benowitz, R. West, C. Russ, T. McRae, D. Lawrence, A. Krishen, L. St Aubin, M. Maravić, R. Anthenelli   +9 more
semanticscholar   +1 more source

Offering e‐cigarettes for smoking cessation and reduction in people with mental illness (ESCAPE): Protocol for a randomized controlled trial

Addiction, Volume 120, Issue 11, Page 2335-2347, November 2025.
Abstract Background and aims Despite a steady decline in smoking rates across the United Kingdom (UK) over the past decades, substantial tobacco‐related inequalities persist, particularly among individuals with mental illness. Smoking prevalence in this group has remained largely unchanged, highlighting a major public health concern.
Dimitra Kale, Emma Beard, Yan Ding, Jodi Pervin, Qi Wu, Catherine Arundel, Steve Parrott, Paul Galdas, Michelle Horspool, Simon Hough, Gregor Russell, Suzy Ker, Elena Ratschen, Lion Shahab   +13 more
wiley   +1 more source

Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism [PDF]

, 2016
Background This study examined whether varenicline (VAR), or naltrexone (NTX), alone or in combination, reduces alcohol drinking in alcohol-preferring (P) rats with a genetic predisposition toward high voluntary alcohol intake.
Dilley, Julian E., Filosa, Nick, Fischer, Stephen M., Froehlich, Janice C., Nicholson, Emily, Rademacher, Logan, Smith, Teal   +6 more
core   +3 more sources

Neuroendocrinology meets addiction: Emerging pharmacotherapies on the horizon

Journal of Internal Medicine, Volume 298, Issue 5, Page 392-423, November 2025.
Abstract Alcohol and other substance use disorders (ASUDs) are prevalent and major contributors to global morbidity and mortality. Their impact extends beyond the individual, imposing significant burdens on families, communities, healthcare systems, and society at large.
Anna Loften, Mehdi Farokhnia, Leandro F. Vendruscolo, Lorenzo Leggio   +3 more
wiley   +1 more source

Population pharmacokinetics and exposure–response analyses of varenicline in adolescent smokers

CPT: Pharmacometrics & Systems Pharmacology, 2021
Varenicline is an approved smoking cessation aid in adults. Population pharmacokinetics (popPK) and exposure–response (ER) (continuous abstinence rates [CAR] weeks 9‒12 and nausea/vomiting incidence) for varenicline in adolescent smokers were ...
Daryl J. Fediuk, Kevin Sweeney, Vaishali Sahasrabudhe, Thomas McRae, Wonkyung Byon   +4 more
doaj   +1 more source

Smoking Cessation Agents and Suicide [PDF]

, 2009
The risk is uncertain, so patients should make an informed ...
Lavigne, Jill E
core   +2 more sources

Mania induced by varenicline [PDF]

F1000Research, 2013
Varenicline is sometimes used in the treatment of smoking addiction. Side effects such as nausea, vomiting, and headaches have been well documented. In addition, depressed mood and suicidal thoughts relating to varenicline usage have been previously reported.
Ping-Tsun Chang, Cheng-Ta Li
openaire   +1 more source